<p><b>(A)</b> Scatter plots (gated on the CD3<sup>+</sup> T-cell population) show co-staining with CD8 and CD161 on representative samples from 5 different clinical groups: CPTNs, CPTPs, HVTNs, HVTPs, and HCs. <b>(B)</b> CD161<sup>++</sup>CD8<sup>+</sup> T (MAIT cell) frequency in HCs showed significantly increased MAIT cell levels compared to other study groups. <b>(C)</b> CD161<sup>+</sup>CD8<sup>+</sup> T cell frequency showed no difference across the different study groups. <b>(D-E)</b> CD161<sup>++</sup>CD8<sup>+</sup> MAIT cell frequency in subjects with HIV mono-infection and HIV/TB co-infection shows no significant correlation with either HIV plasma viral load (copies/mL) or CD4<sup>+</sup> T-cell counts (cells/mm<sup>3</sup>). All ...
<p>Antiviral CD8<sup>+</sup> T-cell capacity measured at 12-months post-infection versus percentage ...
<p>“%CD57 of CD28-” refers to the percentage of CD28−CD8+ T cells expressing CD57.</p
<p>Baseline CD4 T-cell counts (A), immune set point (B) and baseline immune activation (C) versus pr...
<p><b>(A)</b> Zebra plots of double-gating strategy (gated on the CD161<sup>++</sup> CD8<sup>+</sup>...
<p>Figure 2A: FACS plots (gated on the CD3+ T cell population) show CD161 and CD8 co-staining on rep...
<p>Figure 3A: Graph displays CD161++ CD8+ T cell frequency in HIV negative and TB negative subjects ...
<p><b>A</b>) Gating strategy for the characterization of MAIT cells and CD161<sup>-</sup>TCRVα7.2<su...
<p><b>(A)</b> The zebra plots depict the gating strategy for the analysis of expression of CD161 on ...
<p>(A) Representative flow cytometry plots of CMV and HIV-specific CD8 T cells (A*02 CMV and A*03 Ga...
(MTB) endemic African setting.A flow cytometric approach was used to assess the frequency and pheno...
<p>A) Plasma levels of sCD163, sCD14 and IL-18 were measured by ELISA in mostly corresponding sample...
<p>Figure 4A: Graph displaying CD161++CD8+ T cell frequency (median and interquartile range) from 14...
Background: High expression of CD161 on CD8+ T cells is associated with a population of cells though...
<p><b>A</b>) Gating Strategy for CD161 and TCRVα7.2 based MAIT cell characterization in the CD4<sup>...
E. CD4+CD57+ cells. The number in the box in each plot indicates the percentage of CD4+CD57+ lymphoc...
<p>Antiviral CD8<sup>+</sup> T-cell capacity measured at 12-months post-infection versus percentage ...
<p>“%CD57 of CD28-” refers to the percentage of CD28−CD8+ T cells expressing CD57.</p
<p>Baseline CD4 T-cell counts (A), immune set point (B) and baseline immune activation (C) versus pr...
<p><b>(A)</b> Zebra plots of double-gating strategy (gated on the CD161<sup>++</sup> CD8<sup>+</sup>...
<p>Figure 2A: FACS plots (gated on the CD3+ T cell population) show CD161 and CD8 co-staining on rep...
<p>Figure 3A: Graph displays CD161++ CD8+ T cell frequency in HIV negative and TB negative subjects ...
<p><b>A</b>) Gating strategy for the characterization of MAIT cells and CD161<sup>-</sup>TCRVα7.2<su...
<p><b>(A)</b> The zebra plots depict the gating strategy for the analysis of expression of CD161 on ...
<p>(A) Representative flow cytometry plots of CMV and HIV-specific CD8 T cells (A*02 CMV and A*03 Ga...
(MTB) endemic African setting.A flow cytometric approach was used to assess the frequency and pheno...
<p>A) Plasma levels of sCD163, sCD14 and IL-18 were measured by ELISA in mostly corresponding sample...
<p>Figure 4A: Graph displaying CD161++CD8+ T cell frequency (median and interquartile range) from 14...
Background: High expression of CD161 on CD8+ T cells is associated with a population of cells though...
<p><b>A</b>) Gating Strategy for CD161 and TCRVα7.2 based MAIT cell characterization in the CD4<sup>...
E. CD4+CD57+ cells. The number in the box in each plot indicates the percentage of CD4+CD57+ lymphoc...
<p>Antiviral CD8<sup>+</sup> T-cell capacity measured at 12-months post-infection versus percentage ...
<p>“%CD57 of CD28-” refers to the percentage of CD28−CD8+ T cells expressing CD57.</p
<p>Baseline CD4 T-cell counts (A), immune set point (B) and baseline immune activation (C) versus pr...